ArticleCurrent medical science2026
Prognostic Value of Endoplasmic Reticulum Stress-Related Gene Signature in Thyroid Cancer.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo investigate the contribution of endoplasmic reticulum (ER) stress to the progression of thyroid cancer (TC) and to construct a prognostic gene signature.
methodsDifferential expression analysis was performed on 572 samples from The Cancer Genome Atlas (TCGA). ER stress-related genes (ERSGs) were obtained from the GeneCards database. Overlap analysis revealed 178 differentially expressed ERSGs. Least absolute shrinkage and selection operator (LASSO) regression and multivariate Cox regression were used to construct a prognostic risk model. The model was validated in a test set (n = 172) and an independent clinical cohort (n = 90) by RT-qPCR. Immune infiltration, immune checkpoint expression, and drug sensitivity were compared between the high- and low-risk groups using the CIBERSORT algorithm and the Genomics of Drug Sensitivity in Cancer (GDSC) database.
resultsA total of 5,253 differentially expressed genes and 518 ERSGs were identified, yielding 178 overlapping genes. An 11-gene prognostic model (CDKN1A, HTR2A, ATF3, MTTP, BRSK2, EGF, CASP12, HSPA5, IL1A, FOXRED2, CASQ2) was constructed. Patients in the high-risk group had significantly worse overall survival than those in the low-risk group did (log-rank P < 0.001; hazard ratio [HR] = 2.34; 95% CI: 1.58-3.47). The model showed good predictive performance, with AUC values of 0.74, 0.72, and 0.71 for 1-, 3-, and 5-year overall survival, respectively. Significant differences in tumor immune cell infiltration (e.g., Tregs, P < 0.01; M2 macrophages, P < 0.05) and drug sensitivity (e.g., gefitinib, P < 0.05) were detected between the two groups. In 90 clinical samples, the expression patterns of the 11 genes were validated by RT-qPCR (all P < 0.05), which was consistent with the bioinformatics findings.
conclusionThe 11-gene ER stress-related signature independently predicted prognosis in patients with TC across both the TCGA cohort and an independent cohort. This study provides new insight into the role of ER stress in TC and may facilitate the identification of prognostic biomarkers and support clinical decision-making.
Indexed as
Identifiers
42406224What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.